Title: diabetes” title=”Associations of semaglutide with first-time diagnosis of Alzheimer's …”>Semaglutide: The Heart Health Benefits Beyond Weight Loss
Semaglutide, the diabetes drug that’s gaining popularity for its obesity-fighting properties in medications like Ozempic and Wegovy, might have a significant impact on heart health, and not just because it aids weight loss. A recent study on animals suggests that some cardiovascular benefits of the drug may start to show as early as several weeks before noticeable weight loss.
Published in the scientific journal Atherosclerosis, Thrombosis, and Vascular Biology, the study indicates that semaglutide may directly improve arterial and heart muscle conditions. If these findings are replicated in future human clinical trials, it could open up a wide range of potential beneficiaries for the drug, extending beyond those with diabetes or obesity to include individuals with cardiovascular diseases.
How Semaglutide Works
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, used for over a decade in managing type 2 diabetes. These medications mimic the effects of GLP-1, a hormone produced by the intestine that stimulates insulin production and inhibits glucagon release, which raises blood sugar levels. By encouraging insulin secretion and reducing blood sugar levels, semaglutide also helps decrease appetite and promote a sense of fullness.
Semaglutide’s Cardiovascular Benefits
The cardiovascular benefits of semaglutide are well-documented. Numerous clinical studies have shown that the drug can reduce the risk of acute cardiovascular events like strokes and heart attacks. However, the exact reason behind these positive effects remains somewhat unclear. While weight loss certainly contributes to heart health, these benefits often appear before significant weight loss occurs.
Study on Animals
To shed more light on this issue, a team of scientists from Brown University in Rhode Island conducted a trial on 17 pigs that had undergone a procedure to reduce blood flow to the heart, mimicking common cardiovascular problems. After five weeks, the pigs treated with semaglutide showed significant improvements in blood circulation around the affected heart area, as if new blood vessels had formed. They also exhibited reduced cellular death and tissue damage in the heart muscle compared to the untreated pigs.
The Need for Further Research
Future studies are planned to better understand the mechanism behind these benefits. The researchers suggest that previous studies might not have provided clear answers because they did not use high enough dosages or administer the drugs long enough. If semaglutide can indeed offer significant heart health benefits at appropriate doses and durations, it could potentially provide a new avenue for treating cardiovascular diseases.
